Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes
During the last decade, substantial advances have been made in the understanding of the complex molecular, immunological and cellular disturbances involved in the initiation as well as evolution of myelodysplastic syndromes (MDS). In 85% of the mainly frail and older patient population, anemia is pr...
Main Authors: | Anne Sophie Kubasch, Uwe Platzbecker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/16/3853 |
Similar Items
-
Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
by: Simona Pagliuca, et al.
Published: (2021-02-01) -
PERKEMBANGANGADAI EMAS KE INVESTASI EMAS PADA PEGADAIAN SYARIAH
by: Nunung Uswatun Habibah
Published: (2017-02-01) -
Como esa novela
by: Pedro Arturo Estrada
Published: (2019-03-01) -
PERLINDUNGAN HUKUM TERHADAP INVESTOR EMAS
by: Paramita Prananingtyas
Published: (2018-10-01) -
ESA based fiber optical humidity sensor
by: Chen, Qiao
Published: (2011)